Business Wire

Robin.io Platform on QCT Servers Accelerates Cloud-native Transformation

Share

Quanta Cloud Technology (QCT), a global data center solution provider, announced IronCloud — Robin Cloud Platform, its latest addition to its 5G solutions.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210701005022/en/

The partnership between QCT and Robin helps customers accelerate their cloud-native transformations. The solution is built on the Robin.io’s Multi-Data Center Automation Platform (MDCAP) and Cloud Native Platform (CNP), a comprehensive carrier-grade bare-metal to services orchestration and enhanced Kubernetes platform, for 5G and Multi-access Edge Computing (MEC) applications. The solution harmonizes virtual machines and containers, enabling unprecedented resource sharing with easy to use, unified workflows and lifecycle automation that is customer proven to reduce both CAPEX and OPEX. All of this is deployable on QCT servers using 3rd Gen Intel Xeon Scalable processors.

To accelerate cloud-native transformations, QCT and Robin have developed a centralized automation platform using hardware, network acceleration technologies and best practices for orchestration, automation and lifecycle management. The result is an optimized solution that utilizes a cloud-native infrastructure for Telco workloads that supports both virtual machines and containers, in the same resource sharing cluster, from regional data center to far edge. Operators and enterprises can reliably reach the high throughput and low latency required by cloud-native 5G applications (i.e., Core, RAN and CDN). This partnership reduces the challenges of deploying and managing networks, while providing an optimized, cost-efficient infrastructure.

IronCloud — Robin Cloud Platform features the following 3rd Gen Intel Xeon Scalable processor-based servers:

“Lifecycle management and automation are keys to reducing 5G infrastructure and operation costs,” said Mike Yang, president of QCT. “By partnering with Robin.io, we have created an automated cloud-native platform, IronCloud, for our mutual customers to boost 5G application time to market.”

“Our partners are creating optimized, performant and automated solutions that accelerate the path to cloud-native for 5G,” stated Keate Despain, Intel Network Builders and Ecosystem Programs Director. “The IronCloud — Robin Cloud Platform is a solution that will enable companies to deliver an end-to-end cloud native platform and a 5G service delivery network at cost savings.”

“Cloud-Native technology has proven benefits for 5G economics,” said Partha Seetala, CEO and founder of Robin.io. “Our close relationships with QCT and Intel have delivered a production-ready open and extensible platform for deployment and life cycle management. It’s an entire Telco Network Stack, with both CNFs and VNFs that offers industry leading TCO.”

About QCT

QCT is a global data center solution provider that combines the efficiency of hyperscale hardware with infrastructure software from a diversity of industry leaders to solve next-generation data center design and operational challenges. QCT serves cloud service providers, telecoms and enterprises running public, hybrid and private clouds. The parent of QCT is Quanta Computer, Inc., a Fortune Global 500 corporation. www.qct.io

About Robin.io

Robin.io, the 5G and application automation platform company, delivers products that automate the deployment, scaling and life cycle management of data- and network-intensive applications and for 5G service chains across edge, core and RAN. The Robin platform is used globally by companies including BNP Paribas, Palo Alto Networks, Rakuten Mobile, SAP, Sabre and USAA. Robin.io is headquartered in Silicon Valley, California. More at www.robin.io and Twitter: @robin4K8S.

Intel, the Intel logo and other Intel marks are trademarks of Intel Corporation or its subsidiaries. Other names and brands may be claimed as the property of others.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media
Danny Chang (QCT)
Danny_Chang@quantatw.com

Robert Cathey (Cathey.co for Robin.io)
robert@cathey.co

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Moody’s ESG Solutions Launches Solution to Help Investors Assess Alignment With UN Global Compact3.8.2021 10:14:00 CEST | Press release

Moody’s ESG Solutions announced today the launch of its Global Compact Screening tool, which allows market participants to evaluate companies’ alignment with the principles set by the United Nations Global Compact (UNGC), the world’s largest corporate sustainability initiative. Sustainable investment is rising both in volume and as a percentage of assets under management (AUM) globally. Amid this growing focus on responsible investing, Moody’s Global Compact Screening tool provides financial institutions with essential data for portfolio and risk management as well as reporting. It helps investors integrate global ESG standards into their portfolio management practices and develop socially responsible investing (SRI- labelled) funds and indices, while allowing asset owners to evaluate the ESG risk exposure of their portfolio holdings. This type of screening is critical for market participants who are increasingly seeking to follow UNGC standards in their sustainability journey, particu

First half of 2021: Boehringer Ingelheim makes fundamental progress in research and development3.8.2021 10:00:00 CEST | Press release

In the first half of 2021, Boehringer Ingelheim has supplied more humans and animals worldwide with innovative medicines than ever before. The company’s success is based on its rich R&D portfolio with a focus on diseases with high unmet medical need. The R&D pipeline in Human Pharma comprises more than 60 new substances and around 100 clinical and pre-clinical projects. This pipeline has the potential to deliver up to 15 medicines for approval by 2025. In July, Boehringer Ingelheim reported a breakthrough in the treatment of heart failure with empagliflozin (marketed as JARDIANCE®). More than 60 million patients worldwide suffer from this disease, approx. half of them from heart failure with preserved ejection fraction (HFpEF). Heart failure with left ventricular preserved ejection fraction occurs when the left ventricle of the heart is unable to fill properly, resulting in less blood being pumped to the body. A recent trial showed a significantly lower risk with empagliflozin of hospi

Gopher Response to Statement by Playtech, Related Clarifications and Reasons Why Shareholders Should VOTE AGAINST the Consortium Offer3.8.2021 09:09:00 CEST | Press release

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION Gopher Investments (“Gopher”), a 4.97% shareholder in Playtech plc (“Playtech”), is highly disappointed with the Board of Playtech’s decision not to change its recommendation in relation to the offer from Finalto’s management team backed by a consortium led by Barinboim Group (the “Consortium”). Gopher does not believe the supplementary circular contains a full and fair representation of the interaction between Gopher and Playtech since the previous adjournment of the general meeting and therefore wishes to clarify the following chain of events: Gopher responded promptly to an initial information request from the Board, relating to Gopher’s financing and its high confidence of regulatory approval. The Board sought additional information which was commercially conf

SES Networks Expands Partnership With Orange to Enhance Maritime Services3.8.2021 08:50:00 CEST | Press release

Orange maritime customers will now be able to accelerate their digital transformation with higher-capacity satellite connectivity services provided jointly by SES Networks and Orange. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210802005841/en/ SES Networks Expands Partnership With Orange to Enhance Maritime Services (Photo: Business Wire) With this innovative agreement, Orange will integrate its own global infrastructure with the global network coverage powered by SES Networks’ Skala Global Platform. Together it will enable Orange maritime customers to cost-effectively scale up their bandwidth with seamless, ubiquitous and global services. This will ensure they can implement new technologies onboard that take advantage of IoT and AI, as well as edge and cloud applications. The combination of the Orange secured and digital network infrastructure and SES Networks’ Skala Global Platform -- a next-generation technology platf

Relief Announces Receipt of U.S. FDA Orphan Drug Designation for the use of RLF-100 (aviptadil) in the Treatment of Sarcoidosis3.8.2021 07:03:00 CEST | Press release

RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) (“Relief” or the "Company"), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, reported today that, via its newly acquired subsidiary, AdVita Lifescience GmbH, the Company has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (“FDA”) for RLF-100 (aviptadil), an inhaled formulation in development for the treatment of sarcoidosis. RLF-100 is a synthetic form of vasoactive intestinal peptide. In open label exploratory clinical experience in sarcoidosis patients, RLF-100 has been shown to be well tolerated and safe, and to produce favorable immunoregulatory effects in the lungs that have been associated with symptom relief in a significant proportion of the patients. “Receipt of our third Orphan Drug Designation is another important milestone for the Company, as it underscores the potential strength of our pipeline and the high need for be

Smart Engages P.I. Works for Expanded Network Automation Solution3.8.2021 07:00:00 CEST | Press release

Smart Communications, Inc. (Smart), the wireless unit of the Philippines’ largest, fully integrated telecommunications company PLDT, has partnered with P.I. Works for a comprehensive strategy for its Self-Organizing Network (SON) Solution to automate its multi-vendor, multi-technology networks. A self-organizing network (SON) is an automation technology designed to make the planning, configuration, performance management, coverage and quality optimization and healing of mobile radio access networks efficient, simpler and faster. This automation is expected to significantly improve the performancemanagement and service quality enhancements of the Smart wireless network, which will result in an improved experience for Smart customers across the country. Under its Network Operations Transformation program, Smart started working with P.I. Works in 2018 through another entity, to enable Artificial Intelligence (AI) and Machine Learning (ML) technologies for the automation of various network

Personalis, Inc. Publishes New Data Demonstrating a Novel Composite Biomarker NEOPS™ for Predicting Response to Cancer Immunotherapy in Late-Stage Melanoma Patients2.8.2021 22:05:00 CEST | Press release

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced translational genomics and diagnostics for cancer, today announced the publication of its study "Prediction of immunotherapy response in melanoma through combined modeling of neoantigen burden and immune-related resistance mechanisms,"(1) in Clinical Cancer Research, a journal published by the American Association for Cancer Research. The study details the development of the Personalis Neoantigen Presentation Score (NEOPS™), a novel composite biomarker for predicting response to cancer immunotherapy. Enabled by comprehensive tumor immunogenomic profiling from the Personalis NeXT Platform, NEOPS simultaneously models both neoantigen burden and immune-related resistance mechanisms to better predict immunotherapy response in a cohort of late-stage melanoma patients. In this study, NEOPS was more strongly predictive of therapy response than other standard single analyte and investigational biomarkers tested, including tumor mutational b

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom